Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23308739 | 0.89 | HTT (0.46) | ADRB1HTR6HTTMKNK1MKNK2 | |
| SCHEMBL7596615 | 0.73 | MKNK1 (0.50) | HTTMKNK1MKNK2ALDH1A1TP53 | |
| SCHEMBL3417306 | 0.68 | HTT (0.73) | HTTMKNK1MKNK2ALDH1A1POLB | |
| SCHEMBL2186557 | 0.68 | HCAR1 (0.56) | HTTMKNK1MKNK2MAPK1POLB | |
| SCHEMBL30955935 | 0.68 | HCAR1 (0.56) | HTTMKNK1MKNK2MAPK1POLB | |
| SCHEMBL13045147 | 0.66 | NR3C1 (0.43) | ADRB1HTR6 | |
| SCHEMBL23840256 | 0.66 | HTT (0.58) | HTTMKNK1MKNK2ALDH1A1POLB | |
| SCHEMBL29054311 | 0.65 | GSR (0.49) | HTTMKNK1MKNK2ALDH1A1POLB | |
| SCHEMBL23840275 | 0.65 | FGFR1 (0.58) | HTTMKNK1MKNK2ALDH1A1POLB | |
| SCHEMBL23266636 | 0.64 | HTT (0.60) | HTTMKNK1MKNK2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, SERPINB1 | ADRB1 369/4885HTR6 3464/4885HTT 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.